Search tips
Search criteria 


Logo of yjbmLink to Publisher's site
Yale J Biol Med. 1990 Jan-Feb; 63(1): 1–7.
PMCID: PMC2589241

Variability in response to cryoprecipitate treatment for hemostatic defects in uremia.


Cryoprecipitate is frequently administered as treatment for hemostatic defects in patients with uremia. The only published data supporting this approach however, involves seven patients described by Janson and colleagues in whom bleeding times were shortened and bleeding complications reduced after cryoprecipitate infusion. We retrospectively reviewed our institution's experience with cryoprecipitate in this setting. Five patients had sufficiently complete data for evaluation of the efficacy of therapy with cryoprecipitate, including pretreatment bleeding time greater than 15 minutes, normal coagulation studies, and platelet count greater than 100,000/microliters. Two patients had normalization of their bleeding time and a favorable clinical outcome after cryoprecipitate infusion. Three patients failed to shorten their bleeding time after cryoprecipitate infusion or, in one case, multiple infusions. One of these latter patients had correction of his abnormal bleeding time after subsequent administration of deamino-8-D-arginine vasopressin (DDAVP). We conclude that the hemostatic response to cryoprecipitate therapy is variable, and that cryoprecipitate therapy does not achieve restoration of normal hemostasis in some patients with uremic bleeding.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (731K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med. 1980 Dec 4;303(23):1318–1322. [PubMed]
  • Rabiner SF. Uremic bleeding. Prog Hemost Thromb. 1972;1:233–250. [PubMed]
  • Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med. 1985 Nov;79(5):552–559. [PubMed]
  • Rabiner SF, Hrodek O. Platelet factor 3 in normal subjects and patients with renal failure. J Clin Invest. 1968 Apr;47(4):901–912. [PMC free article] [PubMed]
  • Steiner RW, Coggins C, Carvalho AC. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol. 1979;7(2):107–117. [PubMed]
  • Rabiner SF. The effect of dialysis on platelet function of patients with renal failure. Ann N Y Acad Sci. 1972 Oct 27;201:234–242. [PubMed]
  • Stewart JH, Castaldi PA. Uraemic bleeding: a reversible platelet defect corrected by dialysis. Q J Med. 1967 Jul;36(143):409–423. [PubMed]
  • Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983 Jan 6;308(1):8–12. [PubMed]
  • Watson AJ, Keogh JA. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron. 1982;32(1):49–52. [PubMed]
  • Gotti E, Mecca G, Valentino C, Cortinovis E, Bertani T, Remuzzi G. Renal biopsy in patients with acute renal failure and prolonged bleeding time. Lancet. 1984 Oct 27;2(8409):978–979. [PubMed]
  • Maierhoter W, Adams MB, Kleinman JG, Roth DA. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med. 1981 Sep 10;305(11):645–645. [PubMed]
  • Liu YK, Kosfeld RE, Marcum SG. Treatment of uraemic bleeding with conjugated oestrogen. Lancet. 1984 Oct 20;2(8408):887–890. [PubMed]
  • Fernandez F, Goudable C, Sie P, Ton-That H, Durand D, Suc JM, Boneu B. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol. 1985 Jan;59(1):139–148. [PubMed]
  • Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet. 1987 Nov 28;2(8570):1227–1229. [PubMed]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine